Olmesartan medoxomil tablet and preparation method thereof

The invention relates to an olmesartan medoxomil tablet, and belongs to the technical field of pharmaceutical preparations. The olmesartan medoxomil tablet is composed of an olmesartan medoxomil plain tablet and a film coating, wherein the olmesartan medoxomil plain tablet is prepared from the follo...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: FENG ZHANMEI, FAN LIN, YANG XIA, ZHANG JIAZE, HAN ZHIPENG
Format: Patent
Sprache:chi ; eng
Schlagworte:
Online-Zugang:Volltext bestellen
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page
container_title
container_volume
creator FENG ZHANMEI
FAN LIN
YANG XIA
ZHANG JIAZE
HAN ZHIPENG
description The invention relates to an olmesartan medoxomil tablet, and belongs to the technical field of pharmaceutical preparations. The olmesartan medoxomil tablet is composed of an olmesartan medoxomil plain tablet and a film coating, wherein the olmesartan medoxomil plain tablet is prepared from the following components in parts by weight: 6 to 15 parts of olmesartan medoxomil crude drug, 45 to 85 parts of filling agent, 6 to 12 parts of disintegrating agent and 0.5 to 2 parts of lubricating agent; the filling agent is a combination of mannitol, microcrystalline cellulose PH301 and microcrystalline cellulose UF-702. According to the olmesartan medoxomil tablet disclosed by the invention, the filling agent is prepared from two types of microcrystalline cellulose and mannitol in a specific proportion under the situation that no flow aid and no anti-sticking agent are added, the olmesartan medoxomil tablet is prepared by adopting a powder direct pressing method, the production period is shorter, the technology is simp
format Patent
fullrecord <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_CN113893226A</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>CN113893226A</sourcerecordid><originalsourceid>FETCH-epo_espacenet_CN113893226A3</originalsourceid><addsrcrecordid>eNrjZLDyz8lNLU4sKknMU8hNTcmvyM_NzFEoSUzKSS1RSMxLUSgoSi1ILEosycwHKSjJyE9RKMlILUrNT-NhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfHOfoaGxhaWxkZGZo7GxKgBALOJL40</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Olmesartan medoxomil tablet and preparation method thereof</title><source>esp@cenet</source><creator>FENG ZHANMEI ; FAN LIN ; YANG XIA ; ZHANG JIAZE ; HAN ZHIPENG</creator><creatorcontrib>FENG ZHANMEI ; FAN LIN ; YANG XIA ; ZHANG JIAZE ; HAN ZHIPENG</creatorcontrib><description>The invention relates to an olmesartan medoxomil tablet, and belongs to the technical field of pharmaceutical preparations. The olmesartan medoxomil tablet is composed of an olmesartan medoxomil plain tablet and a film coating, wherein the olmesartan medoxomil plain tablet is prepared from the following components in parts by weight: 6 to 15 parts of olmesartan medoxomil crude drug, 45 to 85 parts of filling agent, 6 to 12 parts of disintegrating agent and 0.5 to 2 parts of lubricating agent; the filling agent is a combination of mannitol, microcrystalline cellulose PH301 and microcrystalline cellulose UF-702. According to the olmesartan medoxomil tablet disclosed by the invention, the filling agent is prepared from two types of microcrystalline cellulose and mannitol in a specific proportion under the situation that no flow aid and no anti-sticking agent are added, the olmesartan medoxomil tablet is prepared by adopting a powder direct pressing method, the production period is shorter, the technology is simp</description><language>chi ; eng</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20220107&amp;DB=EPODOC&amp;CC=CN&amp;NR=113893226A$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,777,882,25545,76296</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&amp;date=20220107&amp;DB=EPODOC&amp;CC=CN&amp;NR=113893226A$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>FENG ZHANMEI</creatorcontrib><creatorcontrib>FAN LIN</creatorcontrib><creatorcontrib>YANG XIA</creatorcontrib><creatorcontrib>ZHANG JIAZE</creatorcontrib><creatorcontrib>HAN ZHIPENG</creatorcontrib><title>Olmesartan medoxomil tablet and preparation method thereof</title><description>The invention relates to an olmesartan medoxomil tablet, and belongs to the technical field of pharmaceutical preparations. The olmesartan medoxomil tablet is composed of an olmesartan medoxomil plain tablet and a film coating, wherein the olmesartan medoxomil plain tablet is prepared from the following components in parts by weight: 6 to 15 parts of olmesartan medoxomil crude drug, 45 to 85 parts of filling agent, 6 to 12 parts of disintegrating agent and 0.5 to 2 parts of lubricating agent; the filling agent is a combination of mannitol, microcrystalline cellulose PH301 and microcrystalline cellulose UF-702. According to the olmesartan medoxomil tablet disclosed by the invention, the filling agent is prepared from two types of microcrystalline cellulose and mannitol in a specific proportion under the situation that no flow aid and no anti-sticking agent are added, the olmesartan medoxomil tablet is prepared by adopting a powder direct pressing method, the production period is shorter, the technology is simp</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZLDyz8lNLU4sKknMU8hNTcmvyM_NzFEoSUzKSS1RSMxLUSgoSi1ILEosycwHKSjJyE9RKMlILUrNT-NhYE1LzClO5YXS3AyKbq4hzh66qQX58anFBYnJqXmpJfHOfoaGxhaWxkZGZo7GxKgBALOJL40</recordid><startdate>20220107</startdate><enddate>20220107</enddate><creator>FENG ZHANMEI</creator><creator>FAN LIN</creator><creator>YANG XIA</creator><creator>ZHANG JIAZE</creator><creator>HAN ZHIPENG</creator><scope>EVB</scope></search><sort><creationdate>20220107</creationdate><title>Olmesartan medoxomil tablet and preparation method thereof</title><author>FENG ZHANMEI ; FAN LIN ; YANG XIA ; ZHANG JIAZE ; HAN ZHIPENG</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_CN113893226A3</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>chi ; eng</language><creationdate>2022</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>FENG ZHANMEI</creatorcontrib><creatorcontrib>FAN LIN</creatorcontrib><creatorcontrib>YANG XIA</creatorcontrib><creatorcontrib>ZHANG JIAZE</creatorcontrib><creatorcontrib>HAN ZHIPENG</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>FENG ZHANMEI</au><au>FAN LIN</au><au>YANG XIA</au><au>ZHANG JIAZE</au><au>HAN ZHIPENG</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Olmesartan medoxomil tablet and preparation method thereof</title><date>2022-01-07</date><risdate>2022</risdate><abstract>The invention relates to an olmesartan medoxomil tablet, and belongs to the technical field of pharmaceutical preparations. The olmesartan medoxomil tablet is composed of an olmesartan medoxomil plain tablet and a film coating, wherein the olmesartan medoxomil plain tablet is prepared from the following components in parts by weight: 6 to 15 parts of olmesartan medoxomil crude drug, 45 to 85 parts of filling agent, 6 to 12 parts of disintegrating agent and 0.5 to 2 parts of lubricating agent; the filling agent is a combination of mannitol, microcrystalline cellulose PH301 and microcrystalline cellulose UF-702. According to the olmesartan medoxomil tablet disclosed by the invention, the filling agent is prepared from two types of microcrystalline cellulose and mannitol in a specific proportion under the situation that no flow aid and no anti-sticking agent are added, the olmesartan medoxomil tablet is prepared by adopting a powder direct pressing method, the production period is shorter, the technology is simp</abstract><oa>free_for_read</oa></addata></record>
fulltext fulltext_linktorsrc
identifier
ispartof
issn
language chi ; eng
recordid cdi_epo_espacenet_CN113893226A
source esp@cenet
subjects HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
title Olmesartan medoxomil tablet and preparation method thereof
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T06%3A14%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=FENG%20ZHANMEI&rft.date=2022-01-07&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3ECN113893226A%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true